FOREIGN DNA AND VIRUSES IN VACCINES: What’s the Real Risk?
What’s the risk and where’s the science that our vaccines are contaminated? Three great scientific minds come together to discuss the impact of foreign DNA and retro viruses found in vaccines. This online conference call webinar is being coordinated by The Institute for Pure and Applied Knowledge a not-for-profit organization which exists to perform scientific research in the public interest. This call is hosted by Dr. Lyons-Weiler adn will include special guests Dr. Theresa Deisher and Dr. Judy Mikovitz.
IPAK Educational/Outreach CONFERENCE CALL.
This call is designed with Academia in mind.
Listen to the discussion Monday, Nov 26 2018 7PM EST
Register Here
IPAK
The Institute for Pure and Applied Knowledge is a not-for-profit organization which exists to perform scientific research in the public interest. We use the principles and practices of scientific research to help individual researchers, research teams, consortia, and companies push their project through roadblocks, or map their way around them via evidence-based alternatives. We provide independent views and intellectual effort on scientific progress in three main areas:
- To help investigators in their efforts to reduce human pain & suffering through biomedical and related forms of scientific research.
- To help investigators increase their understanding of the universe using science as a way of knowing.
- To educate the public in robust and reliable advances in medicine and science.
Dr. James Lyon-Weiler
Dr. James Lyons-Weiler, research scientist and author of “Cures vs. Profits“, “Environmental and Genetic Causes of Autism“, and “Ebola:An Evolving Story”. Always looking to improve ways of doing science, he discovered numerous fundamental flaws in the methods for analyzing data. He always strived to provide improved solutions to these problems.
Over the years, given his extensive knowledge of cutting-edge research in cancer and cancer treatments, James helped his sister, his uncle, his future father-in-law, and several close friends find optimal routes to treatment of their cancer. Close friends and family would, on a regular basis, challenge him with statements like “They already have a cure for cancer. They don’t want cures, they want treatments!” While conducting research for “Ebola: An Evolving Story”, it became apparent to him that important and significant improvements could be made to FDA’s approach to gold standard randomized clinical trials. To help sort out these perspectives, using the cumulative benefit of all of these experiences, he is now writing a second book “Cures vs. Profits: Success Stories in Translational Research”, published in May, 2016.
<MORE>
Special Guests:
Dr. Theresa Deisher
Dr. Theresa A. Deisher, PhD is Founder of AVM Biotechnology LLC and also serves as its Chief Executive Officer, President and Chief Scientific Officer. Ms. Deisher served as Vice President of Research and Development of Cellcyte Genetics Corporation. She is an internationally renowned cardiovascular scientist with extensive expertise in the biotechnology industry. Her research programs have encompassed all areas of cardiovascular physiology and disease, including heart failure, myocardial infarction, thrombosis, stroke, diabetes, obesity, hematopoiesis, immune modulation, cardiotoxicity and regenerative medicine. Dr. Deisher was the first scientist to discover and characterize adult cardiac stem cells, for which she holds the patent. Her most recent appointment prior to CellCyte served as Principal Scientist at Amgen, Inc. from July 2002 to September 2006, where she led an interdepartmental team developing antibody therapeutics for the treatment of chronic heart failure, acute myocardial infarction and chemotherapeutic cardiotoxicity.
During her tenure at Amgen, her research group pioneered the use of rodent non-invasive imaging techniques. From October 2000 to August 2006, she served as Senior Staff Scientist, Vascular Biology at Immunex Corp. in Seattle, WA leading projects in Anti-Thrombotics and Inflammation and Myocardial Repair which she successfully transferred over to Amgen with the Immunex acquisition. Her research has resulted in numerous patent awards, out-licensing deals and clinical programs. She has authored numerous manuscripts, has 17 issued or pending patent applications and is a frequent lecturer on stem cell research, inflammation and cardiology. Dr. Deisher received her PhD from Stanford University’s Department of Molecular and Cellular Physiology and her BA degree from Stanford University’s Department of Human Biology, graduating with honors and distinction.
She discovered stem cells in adults and has worked on their potential therapeutic uses. As the result of this work her name is on 23 patents as the inventor. Under her leadership, the SCPI organization
- Studies the health and pathologic consequences of residual fetal human DNA, cellular debris, and retroviruses in our medicines
- Promotes awareness about the widespread use of fetal human material in drug discovery, development and commercialization, and the rights of every consumer to know what is in their products, including residual human DNA
- Supports the gains made in adult stem cell research
- Conducts research and product development, including alternate cell lines for vaccine production
- Applies scientific methods that align with SCPI mission to end human trafficking and exploitation for the purposes of biomedical research and development of commercial products
and
Dr. Judy Mikovits
Dr. Judy A. Mikovits earned a BA in Chemistry with a specialization in biology from the University of Virginia in 1980 and a PhD in biochemistry and molecular biology from George Washington University in 1992.Upon graduation from UVA, she went directly to the National Cancer Institute in Frederick Maryland where she developed purification methods for Interferon alpha. It was this Interferon which was used in the first immune therapy treatment for hairy cell leukemia in 1986. In 1986-7, prior to enrolling in graduate school. she went to Upjohn Pharmaceuticals in Kalamazoo Michigan to develop production methods to insure biological materials manufactured using human blood products were free of contamination from HIV-1. Her PhD thesis defense entitled “Negative Regulation of HIV Expression in Monocytes” changed the paradigm for therapeutic treatment of HIV. For this work, she was awarded the graduate student of the year in 1991. In her thirty-five-year quest to understand and develop therapies for chronic diseases, she has co-authored seminal papers culminating at least a decade of research in each of four fields: immunology, natural products chemistry, epigenetics, and HIV/AIDs drug development.
In 2006, Dr. Mikovits became attracted to the plight of families with neuroimmune diseases including ME/CFS and Autism and was primarily responsible for demonstrating the relationship between environmentally acquired immune dysfunction, chronic inflammation and these diseases. Her pioneering work during a twenty year career at the National Cancer Institute includes the discovery of the modulation of DNA Methylation machinery by human retro viral infection and the development of the concept of inflammatory cytokines and chemokine signatures of infection and disease, which was first published in 1999, when Dr. Mikovits directed the Laboratory of Antiviral Drug Mechanisms in developing therapeutics and diagnostics for HIV/AIDS and AIDS associated malignancies. Therapies which are still standard of care twenty five years later and credited with saving millions of deaths from HIV/AIDS. In 2001, she moved back to industry where she directed the Cancer Biology program of EpiGenX Pharmaceuticals.
The company focused on the development multiplex diagnostic epigenetic and proteomics expression technologies for the prediction of Immune Related Adverse Events to chemotherapy in susceptible populations. In 2006 she co-founded and developed the first neuroimmune research institute dedicated to understanding the pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and related illnesses. In five short years, she won more than 6 million dollars of NIH/DOD competitive funding in grants and contracts for this program. In 2009, Drs. Ruscetti and Mikovits’ labs isolated for the first time a new family of human retroviruses then identified as XMRV. In 2012 it was learned XMRV was a contaminant of the Silverman lab and the XMRVs isolated were a new human exogenous and transmissible retrovirus family, which are strongly associated with neuroimmune disease and cancer. This new family of pathogenic human retroviruses is now called HGRV. Dr. Mikovits has co-authored more than 50 peer reviewed publications and book chapters and the book Plague.
